- Bruker Corporation (BRKR, Financial) launches Beacon Discovery™ at AACR 2025, enhancing live single-cell functional analysis capabilities.
- Beacon Discovery offers a lower cost of ownership, aiming to broaden research accessibility in immuno-oncology and regenerative medicine.
- Pre-orders are now open, with commercial shipments expected by the end of 2025.
Bruker Corporation (BRKR) announced the launch of the Beacon Discovery™ Optofluidic System at the American Association for Cancer Research (AACR) Annual Meeting 2025. This compact benchtop system enhances accessibility to live single-cell functional analysis, providing a stepping stone for academic and biotech laboratories focusing on immuno-oncology, infectious diseases, and cell therapy development.
Beacon Discovery integrates Bruker's proprietary Opto-Electrical Positioning (OEP) technology and OptoSelect™ microfluidic chips to conduct precise multi-parameter and temporal functional analysis. It presents a cost-effective entry point, significantly reducing the barrier for research labs exploring antibody and T Cell Receptor (TCR) discovery.
The new system complements higher-throughput Beacon® platforms designed for automated therapeutic antibody discovery and cell line development. Early-access user, Dr. Joseph Zenga from the Medical College of Wisconsin, emphasized the platform's transformative impact on TCR discovery for cancer immunotherapy.
Dr. Vikram Devgan, Vice President of Global Marketing and Product Management at Bruker Cellular Analysis, remarked, "Beacon Discovery is redefining live single-cell functional analysis. With enhanced ease of use and a lower entry price, we are setting new standards in single-cell functional characterization."
Bruker is also initiating a Technology Access Program (TAP) that allows researchers to submit samples for evaluation on the Beacon Discovery system. Interested parties can pre-order the system now, with commercial shipments expected later in 2025. Attendees of AACR 2025 are invited to Booth #803 for an in-depth experience and to attend Bruker's workshop on April 27th.
